Cancer Database Query Results

PC, Pancreatic Cancer: Click to Expand ⟱
Pancreatic Cancer: Hypoxia (low oxygen tension) is commonly found in solid tumors. Hypoxia-inducible factor-1 (HIF-1),is a key mediator of the cellular response to hypoxia and is overexpressed in a wide variety of solid tumors, including pancreatic cancer.
Nanog is highly expressed in CSCs compared to normal cells [93–97]
HIF-1↑


Scientific Papers found: Click to Expand⟱
1337- 2DG,  Rad,    2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer
- in-vivo, PC, NA
ChemoSen↑, GlucoseCon↓, ROS↑,
5280- 3BP,    Anticancer Efficacy of the Metabolic Blocker 3-Bromopyruvate: Specific Molecular Targeting
- in-vitro, PC, NA
mtDam↑, HK2↓, TGF-β↓, Casp3↑, selectivity↑,
5279- 3BP,  Rad,    Abstract 5243: 3-Bromopyruvate in combination with radiation inhibits pancreatic cancer growth by dismantling mitochondria and ATP generation in a preclinical mouse model
- in-vivo, PC, NA
ATP↓, HK2↓, RadioS↑,
5277- 3BP,    3-Bromopyruvate inhibits pancreatic tumor growth by stalling glycolysis, and dismantling mitochondria in a syngeneic mouse model
- in-vivo, PC, Panc02
HK2↓, selectivity↑, ATP↓, mtDam↑, Dose↝, TumCG↓, Casp3↑, Glycolysis↓, NADPH↓, ATP↓, ROS↑, DNAdam↑, GSH↓, Bcl-2↓, Casp↑, lactateProd↓,
5274- 3BP,    ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
- in-vitro, PC, NA
eff↑, TumCG↓, TumMeta↓, toxicity↝, Glycolysis↓, toxicity↓, Dose↝,
5260- 3BP,    Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
- in-vivo, PC, NA
TumCG↓, toxicity↓, BioAv↝, GAPDH↓, toxicity↑, Dose↝, ATP↓, eff↑, TumCI↓, MMP9↓, toxicity↓,
1- Aco,    Recent development on hyperthermia: An effective cotreatment improving radiotherapy outcome
- in-vitro, PC, PANC1 - in-vitro, Pca, DU145
HH↓, PTCH1↓, Bcl-2↓, Gli1↓,
4558- AgNPs,    Role of Oxidative and Nitro-Oxidative Damage in Silver Nanoparticles Cytotoxic Effect against Human Pancreatic Ductal Adenocarcinoma Cells
- in-vitro, PC, PANC1
ROS↑, selectivity↑, NO↑, SOD↓, GPx4↓, Catalase↓, TumCCA↑, MMP↓,
4541- AgNPs,  RosA,    Eco-friendly synthesis of silver nanoparticles: multifaceted antioxidant, antidiabetic, anticancer, and antimicrobial activities
- in-vitro, Nor, WI38 - in-vitro, BC, MDA-MB-231 - in-vitro, PC, PANC1
*antiOx↑, TumCD↓, selectivity↑,
4411- AgNPs,    Eco-friendly synthesis of silver nanoparticles using Anemone coronaria bulb extract and their potent anticancer and antibacterial activities
- in-vitro, Lung, A549 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, PC3 - in-vitro, Nor, HEK293
AntiCan↑, selectivity↑, Apoptosis↑, TumCCA↑, Bacteria↓, tumCV↓, selectivity↑, Apoptosis↑, TumCCA↑,
343- AgNPs,    Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma
- in-vitro, PC, PANC1
BAX↑, Bcl-2↓, P53↑, TumAuto↑,
375- AgNPs,  ALA,    Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer
- in-vitro, PC, Bxpc-3 - in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vivo, NA, NA
mtDam↑, ROS↑, *toxicity↓, Dose∅, selectivity↑,
303- ALA,  LDN,    The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol
- Case Report, PC, NA
OS↑,
274- ALA,  LDN,    Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases
- Human, PC, NA
OS↑,
5325- ALC,    L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial
- Trial, PC, NA
Weight↑, QoL↑, OS↑,
1158- And,  GEM,    Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer
- in-vitro, PC, NA
TumCP↓, TumCCA↑, Apoptosis↑, STAT3↓, Akt↓, P21↑, BAX↑, cycD1/CCND1↓, cycE/CCNE↓, survivin↓, XIAP↓, Bcl-2↓, Synergy↑,
1354- And,    Andrographolide induces protective autophagy and targeting DJ-1 triggers reactive oxygen species-induced cell death in pancreatic cancer
- in-vitro, PC, NA - in-vivo, PC, NA
Apoptosis↑, DJ-1↓, ROS↑, TumAuto↑, TumCCA↑, TumCP↓, TumW↓, eff↓,
1537- Api,    Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer
- Review, PC, NA
TumCP↓, TumCCA↑, Apoptosis↑, MMPs↓, Akt↓, *BioAv↑, *BioAv↓, Half-Life∅, Hif1a↓, GLUT1↓, VEGF↓, ChemoSen↑, ROS↑, Bcl-2↓, Bcl-xL↓, BAX↑, BIM↑,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, Synergy↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
589- Api,  5-FU,    Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro
- in-vitro, PC, Bxpc-3
GSK‐3β↓, NF-kB↓,
315- Api,    Apigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer
- vitro+vivo, PC, Panc02
CK2↓, CD4+↑, CD8+↑, Ikaros↑,
1362- Ash,  GEM,    Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A
- in-vitro, PC, PANC1 - in-vitro, PC, Hs766t
ChemoSen↑, ROS↑, Apoptosis↑, TumCMig↓, F-actin↓, YMcells↓, NF-kB↓,
2003- Ash,    Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Nor, TIG-1 - in-vitro, PC, LNCaP
TumCD↑, selectivity↑, cFos↑, ROS↑, *ROS∅, HSP70/HSPA5↑, Apoptosis↑, ER Stress↑, TumCCA↑,
5395- Ash,    Withaferin A Targets Heat Shock Protein 90 in Pancreatic Cancer Cells
- vitro+vivo, PC, PANC1 - in-vitro, PC, MIA PaCa-2
TumCP↓, HSP90↓, Akt↓, CDK4↓, TumCG↓, Apoptosis↑, AntiCan↑,
2597- Ba,    Baicalein – An Intriguing Therapeutic Phytochemical in Pancreatic Cancer
- Review, PC, NA
chemoP↑, ChemoSen↑, 12LOX?, Bcl-2↓, BAX↑, Mcl-1↓, ERK↓, Prx6↑, Dose↝, BioAv↓, eff↑,
1384- BBR,    Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines
- in-vitro, PC, PANC1
TumCCA↑, ROS↑, Apoptosis↑,
940- BBR,    Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression
- vitro+vivo, PC, PANC1 - in-vivo, PC, MIA PaCa-2
LDHA↓, lactateProd↓, AMPKα↓, TumVol↓, Ki-67↓,
5637- BCA,  ATV,    Combination Treatment of Biochanin A and Atorvastatin Alters Mitochondrial Bioenergetics, Modulating Cell Metabolism and Inducing Cell Cycle Arrest in Pancreatic Cancer Cells
- in-vitro, PC, AsPC-1 - in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2
Synergy↑, TumCI↓, STAT3↓, Apoptosis↑,
5510- bemA,    Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion
- in-vitro, BC, MDA-MB-231 - in-vitro, PC, NA
eff↑, Apoptosis↑, TumCI↓, ACLY↓, LDL↓, eff↑, TumCP↓,
8- BetA,    Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana
- in-vitro, PC, HaCaT - in-vitro, Pca, PANC1
HH↓, Gli1↓, PTCH1↓, Bcl-2↓,
2750- BetA,  GEM,    Betulinic acid, a major therapeutic triterpene of Celastrus orbiculatus Thunb., acts as a chemosensitizer of gemcitabine by promoting Chk1 degradation
- in-vitro, PC, Bxpc-3 - in-vitro, Lung, H1299
CHK1↓, ChemoSen↑, tumCV↓, Apoptosis↑, DNAdam↑,
5722- BF,    Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells
- in-vitro, PC, PANC1
Apoptosis↑, TumCCA↑, HSP27↓, p‑Akt↓, proCasp3↑, proCasp9↑, Bcl-2↝, BAX↝, Synergy↑,
5716- BF,    Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, or Pancreatic Cancer
- Trial, NSCLC, NA - Trial, PC, NA - Trial, HCC, NA
Dose↝, toxicity↓, other↓, QoL↑, OS?,
9201- BITC,    Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells
- in-vitro, PC, Bxpc-3 - in-vitro, PC, Capan-2 - in-vitro, Nor, HPDE-6
NF-kB↓, HDAC1↓, HDAC3↓,
9208- BITC,    Benzyl Isothiocyanate-Induced DNA Damage Causes G2/M Cell Cycle Arrest and Apoptosis in Human Pancreatic Cancer Cells
- in-vitro, PC, Capan-2
p‑γH2AX↑, TumCD↑, TumCCA↑, P21↑, cycD1/CCND1↓, CDC2↓, CDC25↓, DNAdam↑,
9212- BITC,    Benzyl isothiocyanate sensitizes human pancreatic cancer cells to radiation by inducing apoptosis
- in-vitro, PC, Panc02 - in-vitro, PC, MIA PaCa-2
eff↝, RadioS↑, XIAP↓, IAP1↓, APAF1↑,
9166- BITC,    Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3
- in-vitro, PC, Bxpc-3 - in-vitro, PC, Panc02
STAT3↓, TumCMig↓, TumCI↓, VEGF↓, MMP2↓, Hif1a↓, CD31/PECAM-1↓,
9163- BITC,    Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells
- in-vitro, PC, Capan1
Apoptosis?, p‑ERK↑, JNK↑, ROS↑, GSH↓, eff↓, BAX↑, cl‑Casp3↑, cl‑PARP↑, selectivity↑,
9198- BITC,    Benzyl Isothiocyanate–Mediated Inhibition of Histone Deacetylase Leads to NF-κB Turnoff in Human Pancreatic Carcinoma Cells
- in-vitro, PC, Bxpc-3 - in-vitro, PC, Capan1
Apoptosis↑, NF-kB?, HDAC1↓, HDAC3↓, selectivity↑,
9196- BITC,    Benzyl Isothiocyanate Inhibits Epithelial-Mesenchymal Transition in Cultured and Xenografted Human Breast Cancer Cells
- vitro+vivo, BC, MDA-MB-231 - in-vitro, PC, PL45
TumCG↓, EMT↓, E-cadherin↑, OCLN↑, Vim↓, Fibronectin↓, Snail↓, cMET↓, Slug↓,
5688- BJ,    Brucea Javanica Oil Emulsion Injection inhibits proliferation of pancreatic cancer via regulating apoptosis-related genes
- vitro+vivo, PC, MIA PaCa-2
TumCG↓, TumCI↓, TumCCA↑, Apoptosis↑, BAX↑, cl‑Casp3↑, Bcl-2↓, MMP2↓, BACE/β-secretase↓, TOP2↓,
755- Bor,    https://aacrjournals.org/cancerres/article/67/9_Supplement/4220/535557/Boric-acid-induces-apoptosis-in-both-prostate-and
- in-vitro, Pca, DU145 - in-vitro, PC, PC3
TumCG↓, Apoptosis↑,
3525- Bor,    Synthesis of DNA-Boron Cluster Composites and Assembly into Functional Nanoparticles with Dual, Anti-EGFR, and Anti-c-MYC Oncogene Silencing Activity
- in-vitro, PC, PANC1
EGFR↓, cMyc↓,
1423- Bos,    Acetyl-11-keto-β-Boswellic Acid Suppresses Invasion of Pancreatic Cancer Cells Through The Downregulation of CXCR4 Chemokine Receptor Expression
- in-vitro, Melanoma, U266 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, SkBr3 - in-vitro, PC, PANC1
CXCR4↓, TumCI↓, HER2/EBBR2↓, NF-kB↓,
6547- BSB,    Antitumor effects of a-bisabolol against pancreatic cancer
- vitro+vivo, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, KLM1 - in-vitro, PC, KP4 - in-vitro, Nor, ACBRI515
TumCP↓, selectivity↑, Apoptosis↑, Akt↓, EGR1↑, TumCG↓, Dose↝, PI3K↓, PDK1 / PDPK1↓, mTORC2↑,
6546- BSB,    α-Bisabolol Inhibits Invasiveness and Motility in Pancreatic Cancer Through KISS1R Activation
- in-vitro, PC, NA
Apoptosis↑, TumCI↓, KISS1↑,
6555- BSB,    Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer
- vitro+vivo, PC, NA
TumCP↓, TumCI↓, p‑FAK↓, TumVol↓, Ki-67↓,
145- CA,  CUR,    The anti-cancer effects of carotenoids and other phytonutrients resides in their combined activity
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, PC, DU145
AR↓, ARE/EpRE↑, TumCP↓, PSA↓,
5836- CAP,    In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway
- vitro+vivo, PC, AsPC-1 - in-vitro, PC, Bxpc-3
tumCV↓, Apoptosis↑, ROS↑, MMP↓, eff↓, BAX↑, Bcl-2↓, survivin↓, Cyt‑c↑, AIF↑, selectivity↑, JNK↑, TumCG↓,
2014- CAP,    Role of Mitochondrial Electron Transport Chain Complexes in Capsaicin Mediated Oxidative Stress Leading to Apoptosis in Pancreatic Cancer Cells
- in-vitro, PC, Bxpc-3 - in-vitro, Nor, HPDE-6 - in-vivo, PC, AsPC-1
ROS↑, *ROS∅, selectivity↑, compI↓, compIII↓, eff↑, selectivity↑, ATP↓, Cyt‑c↑, Casp9↑, Casp3↑, MMP↓, SOD↓, GSH/GSSG↓, Apoptosis↑, *toxicity∅, GSH↓, Catalase↓, GPx↓, Dose↝,

Showing Research Papers: 1 to 50 of 199
Page 1 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 199

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   antiOx⇅, 1,   ARE/EpRE↑, 1,   Catalase↓, 2,   DJ-1↓, 1,   GPx↓, 2,   GPx4↓, 1,   GSH↓, 9,   GSH↑, 2,   GSH⇅, 1,   GSH/GSSG↓, 1,   H2O2↑, 3,   HO-1↓, 1,   HO-1↑, 2,   Iron↑, 2,   lipid-P↑, 2,   MDA↑, 1,   NQO1↑, 1,   NRF2↑, 3,   Prx6↑, 1,   ROS↓, 1,   ROS↑, 50,   ROS⇅, 1,   ROS∅, 2,   mt-ROS↑, 1,   SOD↓, 3,   SOD↑, 1,   SOD2↑, 1,   TBARS↓, 1,   Thiols↓, 1,   Trx↓, 1,   Trx2↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,   Ikaros↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↓, 1,   CDC2↓, 1,   CDC25↓, 1,   compI↓, 1,   compIII↓, 1,   compV↓, 1,   EGF↓, 1,   ETC?, 1,   MFN2↓, 1,   mitResp↓, 1,   mtDam↑, 7,   OCR↓, 5,   PDH↑, 1,   p‑PDH↓, 1,   PINK1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX?, 1,   5LO↓, 1,   ACC↓, 1,   ACLY↓, 2,   AMPK↑, 6,   ARG↓, 1,   ATP↓, 9,   i-ATP↑, 1,   CAIX/CA9↓, 1,   citrate↓, 1,   ECAR↓, 4,   FASN↓, 2,   GAPDH↓, 1,   GlucoseCon↓, 5,   Glycolysis↓, 8,   GSK‐3β↓, 1,   HK2↓, 5,   HK2∅, 1,   lactateProd↓, 5,   LDHA↓, 4,   LDHA∅, 1,   LDL↓, 1,   lipoGen↓, 1,   NADPH↓, 2,   PDK1 / PDPK1↓, 2,   PDKs↓, 1,   PFK↓, 1,   PFKP↓, 1,   PKM2↓, 4,   PPP↓, 1,   Pyruv↓, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

AIF↑, 3,   APAF1↑, 1,   Apoptosis?, 1,   Apoptosis↑, 73,   mt-Apoptosis↑, 1,   BAD↑, 1,   BAX↑, 17,   BAX↝, 1,   Bax:Bcl2↑, 3,   Bcl-2↓, 25,   Bcl-2↝, 1,   Bcl-xL↓, 6,   cl‑BID↑, 1,   BIM↑, 2,   Casp↑, 5,   Casp↝, 1,   Casp∅, 1,   proCasp↑, 1,   Casp10↓, 1,   Casp3↑, 21,   cl‑Casp3↑, 8,   cl‑Casp3∅, 1,   proCasp3↑, 1,   Casp7↑, 4,   Casp8↓, 1,   Casp8↑, 4,   cl‑Casp8↑, 1,   Casp9↑, 7,   proCasp9↑, 1,   Cyt‑c↑, 7,   FasL⇅, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 2,   HEY1↓, 1,   IAP1↓, 2,   Mcl-1↓, 5,   MLKL↑, 1,   p‑MLKL↓, 1,   Necroptosis↑, 1,   necrosis↑, 1,   p38↓, 1,   p38↑, 3,   p‑p38↑, 1,   RIP3↑, 1,   p‑RIP3↑, 1,   survivin↓, 11,   TumCD↓, 1,   TumCD↑, 8,   XIAP↓, 7,   β-TRCP↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 15,   p‑Akt↓, 7,   AMPKα↓, 1,   CaMKII ↓, 1,   CIP2A↓, 1,   CK2↓, 1,   cMET↓, 2,   EGFR↓, 3,   p‑EGFR↓, 2,   ERK↓, 5,   p‑ERK↓, 1,   p‑ERK↑, 2,   HER2/EBBR2↓, 1,   IGFR↓, 1,   p‑IGFR↓, 1,   IKKα↓, 2,   p‑IKKα↓, 1,   JAK2↓, 3,   JNK↑, 6,   p‑JNK↓, 1,   p‑JNK↑, 1,   MAPK↓, 2,   MAPK↑, 1,   MEK↑, 1,   mTOR↓, 6,   mTOR↑, 1,   p‑mTOR↓, 1,   mTORC2↑, 1,   p‑p70S6↓, 1,   PDGFRA↓, 2,   PI3K↓, 7,   PI3K/Akt↓, 2,   PI3k/Akt/mTOR↓, 1,   PKA↓, 1,   PTEN↑, 3,   Sp1/3/4↓, 2,   STAT3↓, 11,   STAT3↑, 1,   p‑STAT3↓, 1,   STAT5↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↑, 2,   cMyc↓, 8,   DNMT1↓, 1,   EZH2↓, 1,   H4↑, 1,   ac‑H4↑, 1,   HATs↑, 1,   HDAC↓, 7,   HDAC1↓, 3,   HDAC2↓, 2,   HDAC3↓, 3,   KISS1↑, 1,   miR-148a↑, 1,   miR-200c↑, 1,   miR-21↝, 1,   miR-340↑, 1,   OCT4↓, 5,   other↓, 3,   other↝, 1,   SOX2↓, 2,   tumCV↓, 26,   tumCV↑, 1,   UTF1↑, 1,   YMcells↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 1,   CHOP/DDIT3↑, 2,   eIF2α↑, 1,   ER Stress↑, 4,   GRP78/BiP↓, 1,   GRP78/BiP↑, 1,   HSP27↓, 1,   HSP70/HSPA5↓, 1,   HSP70/HSPA5↑, 2,   HSP90↓, 2,   p‑IRE1↑, 1,   PERK↑, 2,   UPR↑, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   ATG7↑, 1,   Beclin-1/ATG6↑, 3,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3A↑, 1,   LC3B↑, 2,   LC3II↓, 1,   LC3II↑, 1,   lysoMP↑, 1,   MitoP↓, 1,   MitoP↑, 1,   p62↓, 2,   p62↑, 2,   PARK2↑, 1,   TumAuto↓, 1,   TumAuto↑, 8,   TumAuto⇅, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 11,   P53↑, 5,   p‑P53↑, 1,   p73↑, 1,   PARP↝, 1,   p‑PARP↑, 1,   cl‑PARP↑, 9,   cl‑PARP∅, 1,   PCNA↓, 2,   SAPK↑, 1,   TOP2↓, 2,   γH2AX↑, 2,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1/2/5/9↓, 1,   CDK2↓, 3,   CDK4↓, 3,   CDK6↓, 2,   CHK1↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 11,   cycD1/CCND1↑, 1,   cycE/CCNE↓, 2,   Ki-67↓, 9,   P21↑, 7,   p27/CDKN1B↑, 1,   TumCCA↓, 1,   TumCCA↑, 32,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 2,   CD133↓, 2,   CD34↓, 1,   cFos↑, 1,   CSCs↓, 5,   CSCsMark↓, 1,   FOSL1↑, 1,   Gli↓, 2,   Gli1↓, 13,   HH↓, 13,   IGF-1↓, 2,   Jun↓, 1,   Ki-67↓, 9,   Nanog↓, 4,   NOTCH↓, 1,   NOTCH1↓, 2,   NOTCH3↓, 1,   PTCH1↓, 6,   PTCH2↓, 1,   Shh↓, 6,   Smo↓, 5,   Sufu↓, 1,   TumCG↓, 44,   TumCG↑, 3,   TumCG∅, 1,   TumCP↓, 53,   TumCP⇅, 1,   Wnt↓, 3,  

Migration(tgid=13) ⓘ

ARG1/2↑, 1,   Ca+2↓, 1,   Ca+2↑, 4,   i-Ca+2↓, 1,   i-Ca+2↑, 1,   CAFs/TAFs↓, 1,   E-cadherin↑, 9,   EMT↓, 16,   F-actin↓, 1,   FAK↓, 1,   p‑FAK↓, 2,   Fibronectin↓, 1,   GLI2↓, 5,   MMP14↓, 1,   MMP2↓, 7,   MMP7↓, 1,   MMP9↓, 10,   MMPs↓, 3,   MMPs↝, 1,   MUC1↓, 1,   MUC4↓, 3,   N-cadherin↓, 5,   NEDD9↓, 1,   PAK1↓, 1,   Rho↓, 1,   ROCK1↓, 1,   Slug↓, 3,   p‑SMAD2↓, 2,   p‑SMAD3↓, 2,   Snail↓, 6,   SPARC↑, 2,   TGF-β↓, 3,   TGF-β↑, 1,   TIMP2↑, 1,   TSP-1↑, 1,   TumCI↓, 32,   TumCI↑, 1,   TumCMig↓, 25,   TumMeta↓, 6,   uPA↓, 2,   uPAR↓, 1,   Vim↓, 6,   Zeb1↓, 4,   α-SMA↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 6,   CD31/PECAM-1↓, 1,   EGR1↑, 1,   HIF-1↓, 1,   Hif1a↓, 8,   NO↓, 1,   NO↑, 1,   VEGF↓, 15,   VEGF↝, 1,   VEGFR1↓, 1,   VEGFR2/KDR/Flk1↓, 3,  

Barriers & Transport(tgid=15) ⓘ

CellMemb↑, 2,   EPR↑, 1,   GLUT1↓, 4,   GLUT4↓, 1,   MMP↓, 20,   MMP∅, 1,   OCLN↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   CD44↓, 1,   CD8+↑, 2,   COX1↓, 1,   COX2/PTGS2↓, 7,   CXCL12↓, 1,   CXCR4↓, 2,   Eos↑, 1,   ICAM-1↓, 1,   IL1β↓, 1,   IL6↓, 3,   IL8↓, 1,   Imm↑, 5,   Inflam↓, 2,   pol-M1↑, 1,   M2 MC↓, 1,   pol-M2 MC↓, 1,   MCP1/CCL2↓, 2,   NAF1↓, 1,   NF-kB?, 1,   NF-kB↓, 25,   NF-kB↝, 1,   NK cell↑, 1,   p50↓, 1,   p65↓, 4,   PD-L1↓, 1,   PGE1↓, 1,   PGE2↓, 1,   PSA↓, 1,   TNF-α↓, 2,   Treg lymp↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

pH↑, 2,   e-pH↑, 1,   TAMS↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

CAXII/CA12↑, 1,  

Protein Aggregation(tgid=19) ⓘ

BACE/β-secretase↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↓, 1,   BioAv↑, 2,   BioAv↝, 3,   ChemoSen↑, 24,   ChemoSen∅, 1,   Dose?, 3,   Dose↓, 1,   Dose↝, 16,   Dose∅, 4,   eff↓, 18,   eff↑, 27,   eff↝, 4,   eff∅, 1,   GSTP1/GSTπ↑, 1,   Half-Life↝, 1,   Half-Life∅, 1,   RadioS↑, 4,   selectivity↓, 1,   selectivity↑, 30,   Synergy↑, 17,   Synergy∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALB∅, 1,   AR↓, 2,   CA19-9↓, 1,   CRP∅, 1,   EGFR↓, 3,   p‑EGFR↓, 2,   EZH2↓, 1,   Ferritin↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 3,   LDH↓, 3,   PD-L1↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 5,   antiNeop↑, 1,   AntiTum↑, 3,   cachexia↓, 1,   chemoP↑, 1,   chemoPv↑, 1,   neuroP↑, 1,   OS?, 1,   OS↑, 11,   QoL↑, 2,   QoL∅, 1,   radioP↑, 1,   Risk↓, 3,   Strength↑, 1,   toxicity↓, 6,   toxicity↑, 2,   toxicity↝, 1,   TumVol↓, 12,   TumW↓, 8,   Weight↑, 1,   Weight∅, 3,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 440

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 3,   GSH↑, 1,   MDA↓, 2,   ROS↓, 1,   ROS∅, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ETC↝, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

FASN↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG∅, 1,  

Migration(tgid=13) ⓘ

TumCI∅, 1,   TumCMig∅, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

CEA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoPv↑, 1,   toxicity↓, 5,   toxicity↑, 1,   toxicity∅, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiP↑, 1,  
Total Targets: 20

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:21  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page